| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
Isethionic acid sodium salt is an endogenous metabolite that is found in human plasma and urine. As an endogenous compound, it interacts with various metabolic pathways. Higher plasma levels of isethionic acid sodium salt have been shown to be protective against type 2 diabetes, suggesting that it may play a role in glucose metabolism or insulin sensitivity. The compound is an organosulfur compound containing a short-chain alkylsulfonate linked to a hydroxyl group. It may interact with various enzymes and transporters involved in sulfur metabolism. As a surfactant, it may interact with cell membranes and affect membrane fluidity and permeability. However, the compound's specific molecular targets have not been extensively characterized. Its role as a metabolite of taurine suggests that it may be involved in the regulation of taurine levels and taurine-mediated processes such as osmoregulation, antioxidation, and modulation of calcium signaling.
|
|---|---|
| ln Vitro |
In vitro, isethionic acid sodium salt is used as an endogenous metabolite in biochemical research. The compound is found in both human plasma and urine. Higher plasma levels of isethionic acid sodium salt have been shown to be protective against type 2 diabetes. In cell-based assays, the compound is tested for its effects on glucose metabolism, insulin sensitivity, and other metabolic processes. The compound's surfactant properties make it useful for studying membrane interactions and detergent effects on cells. In studies of sulfur metabolism, isethionic acid sodium salt is used to study the metabolism of taurine and other sulfur-containing compounds. The compound's amphoteric nature (having both positive and negative charges) makes it useful for studying protein-surfactant interactions and for use in various biochemical assays. However, detailed in vitro activity data are limited.
|
| ln Vivo |
In vivo, higher plasma levels of isethionic acid sodium salt have been shown to be protective against type 2 diabetes. The compound is an endogenous metabolite that is found in human plasma and urine. It is synthesized via taurine through a possible enzymatic deamination process. The compound's in vivo effects are thought to be related to its role in sulfur metabolism and its potential effects on glucose metabolism and insulin sensitivity. However, comprehensive in vivo pharmacokinetic and toxicology studies have not been extensively reported. Further in vivo studies are needed to fully characterize the compound's physiological role and therapeutic potential. The compound is classified as a research chemical and is not approved for human use.
|
| Enzyme Assay |
In vitro enzyme and receptor binding assays for isethionic acid sodium salt are not well documented. As an endogenous metabolite, it may interact with various metabolic enzymes. For example, it may be a substrate or product of enzymes involved in taurine metabolism, such as taurine dehydrogenase or transaminase. In these assays, the enzyme is incubated with isethionic acid sodium salt and other substrates, and the formation of products is measured. The compound may also interact with transporters involved in the uptake and efflux of organic anions and cations. However, specific assay protocols have not been extensively reported. The compound's surfactant properties may interfere with some biochemical assays, and appropriate controls should be included to account for these effects.
|
| Cell Assay |
In vitro cell-based assays for isethionic acid sodium salt are limited. The compound is studied primarily in biochemical systems. In studies of glucose metabolism, cells (e.g., adipocytes, hepatocytes, pancreatic beta cells) are cultured in appropriate medium and treated with isethionic acid sodium salt at various concentrations. Following treatment, glucose uptake, insulin secretion, and other metabolic parameters are measured. The compound's effects on cell viability and membrane integrity are assessed using standard assays (e.g., MTT, LDH release). Each experiment includes appropriate controls (untreated cells, vehicle controls) and is performed in triplicate to ensure statistical reliability. The compound is typically dissolved in water or buffer for use in these assays, due to its high solubility.
|
| Animal Protocol |
In vivo animal experiments with isethionic acid sodium salt are limited. The compound is an endogenous metabolite that is found in human plasma and urine. Studies have focused on its role as an endogenous metabolite rather than as a therapeutic agent. However, animal studies could be conducted to investigate the effects of isethionic acid sodium salt on glucose metabolism, insulin sensitivity, and other metabolic processes. In these studies, the compound would be administered via oral gavage or intravenous injection, and blood glucose, insulin, and other metabolic parameters would be measured. All animal procedures would be conducted in accordance with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of isethionic acid sodium salt are characteristic of a small, highly polar molecule. With a molecular weight of 148.11 g/mol and a sulfonate group, the compound is highly water-soluble and is expected to have limited oral bioavailability due to its polarity. Following absorption, the compound is distributed primarily in the extracellular space and is rapidly cleared by the kidneys through glomerular filtration. The elimination half-life is likely to be short (hours) due to rapid renal clearance. The compound is an endogenous metabolite and is metabolized through endogenous pathways. Its pharmacokinetic profile makes it suitable for studying renal function and organic anion transport. As with all research chemicals, appropriate pharmacokinetic studies should be conducted to fully characterize the compound's absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
The CIR expert panel concluded that the following 12 hydroxyethyl sulfonates are safe for use in cosmetics at current methods and concentrations, provided the formulation ensures they do not irritate the skin… Sodium hydroxyethyl sulfonate… Safe for use in cosmetics under specific conditions. The toxicological profile of isethionic acid sodium salt has not been extensively characterized in formal toxicology studies. As an endogenous metabolite that is found in human plasma and urine, the compound is naturally present in the body and is expected to be relatively non-toxic at physiological concentrations. The compound is used as a mild surfactant in personal care products, indicating low dermal toxicity. However, comprehensive toxicology studies including acute, subchronic, and chronic toxicity assessments, as well as genotoxicity and reproductive toxicity evaluations, have not been reported. The compound is classified as a research chemical and is not approved for human use. Standard safety precautions should be observed when handling the compound, including the use of appropriate personal protective equipment. |
| Additional Infomation |
colorless, viscous, strongly acidic liquid that can form a detergent with oleic acid.
Isethionic acid sodium salt is a valuable research tool for studying sulfur metabolism, metabolic disorders, and surfactant chemistry. It is an endogenous metabolite that mammals can synthesize via taurine through a possible enzymatic deamination process. The compound is found in both human plasma and urine. It has the molecular formula C₂H₅NaO₄S and a molecular weight of 148.11 g/mol. Higher plasma levels of isethionic acid sodium salt have been shown to be protective against type 2 diabetes. The compound is an organosulfur compound containing a short-chain alkylsulfonate linked to a hydroxyl group. It is not approved for any clinical indication and is strictly for research use only. Its role as an endogenous metabolite and its surfactant properties make it a useful tool for studying metabolism, membrane biology, and industrial applications. |
| Molecular Formula |
C2H5NAO4S
|
|---|---|
| Molecular Weight |
148.11
|
| Exact Mass |
147.98
|
| CAS # |
1562-00-1
|
| Related CAS # |
Isethionic acid;107-36-8
|
| PubChem CID |
517063
|
| Appearance |
White to off-white solid powder
|
| Density |
1.625g/cm3
|
| Melting Point |
191-194 °C(lit.)
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
8
|
| Complexity |
122
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(CS(=O)(=O)[O-])O.[Na+]
|
| InChi Key |
LADXKQRVAFSPTR-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C2H6O4S.Na/c3-1-2-7(4,5)6;/h3H,1-2H2,(H,4,5,6);/q;+1/p-1
|
| Chemical Name |
sodium;2-hydroxyethanesulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (675.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7517 mL | 33.7587 mL | 67.5174 mL | |
| 5 mM | 1.3503 mL | 6.7517 mL | 13.5035 mL | |
| 10 mM | 0.6752 mL | 3.3759 mL | 6.7517 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
